Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7793594 | 0.85 | KMT2A (0.49) | KMT2AMEN1KDM4EHPGDALDH1A1 | |
| SCHEMBL6867070 | 0.79 | MAOB (0.51) | KMT2AMEN1KDM4EHPGDALDH1A1 | |
| SCHEMBL6869569 | 0.78 | MAOA (0.43) | KMT2AMEN1KDM4EHPGDALDH1A1 | |
| SCHEMBL7793591 | 0.76 | MAOA (0.47) | KMT2AMEN1KDM4EHPGDALDH1A1 | |
| SCHEMBL6869570 | 0.76 | MAOA (0.43) | KMT2AMEN1KDM4EHPGDALDH1A1 | |
| SCHEMBL6867087 | 0.73 | RAB9A (0.39) | KMT2AMEN1KDM4EHPGDALDH1A1 | |
| SCHEMBL6867371 | 0.73 | ALDH1A1 (0.56) | KMT2AMEN1KDM4EHPGDALDH1A1 | |
| SCHEMBL7794175 | 0.71 | GBA1 (0.42) | KMT2AKDM4EHPGDALDH1A1MAOA | |
| SCHEMBL6864371 | 0.70 | NPC1 (0.45) | KMT2AMEN1KDM4EHPGDALDH1A1 | |
| SCHEMBL6867776 | 0.69 | GBA1 (0.44) | KMT2AMEN1KDM4EHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6812331-B2 | BACTERICIDES | AVENTIS PHARMA S.A. (FR) | 2004-11-02 | — | — | US | disclosed |
| US-6350733-B1 | 4-HYDROXYBENZOPYRAN-2-ONE DERIVATIVES; BACTERICIDES FOR STAPHYLOCOCCUS INFECTIONS; SKIN DISORDERS | AVENTIS PHARMA S.A. (FR) | 2002-02-26 | — | — | US | disclosed |
| US-20020010322-A1 | New aromatic derivatives substituted by a ribose, their preparation process and their use as medicaments | AVENTIS PHARMA S.A. | 2002-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010322-A1 | New aromatic derivatives substituted by a ribose, their preparation process and their use as medicaments | RPIA, CD38, PARP1 | KMT2A 1234/4885MEN1 3924/4885KDM4E 1566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.